

University of Groningen

On the relevance of carnosine and carnosinase for the development of diabetic nephropathy

Riedl, Eva Maria Susanne

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2011

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Riedl, E. M. S. (2011). *On the relevance of carnosine and carnosinase for the development of diabetic nephropathy*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

REFERENCES

1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, *et al.* The importance of diabetic nephropathy in current nephrological practice. *Nephrol Dial Transplant* 2003; **18**: 1716-1725.
2. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. *Am J Kidney Dis* 1999; **34**: 795-808.
3. Remuzzi G, Schieppati A, Ruggenti P. Nephropathy in Patients with Type 2 Diabetes. *New England Journal of Medicine* 2002; **346**: 1145-1151.
4. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. *Kidney Int* 1995; **47**: 1703-1720.
5. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. *New England Journal of Medicine* 2005; **353**: 2643-2653.
6. Adler AI, Stevens RJ, Manley SE, Bilous RW, *et al.* Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). *Kidney Int* 2003; **63**: 225-232.
7. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, *et al.* Diabetic nephropathy: diagnosis, prevention, and treatment. *Diabetes Care* 2005; **28**: 164-176.
8. Haffner SM, Gonzales C, Valdez RA, Mykkanen L, *et al.* Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. *Diabetologia* 1993; **36**: 1002-1006.
9. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. *Arch Intern Med* 1997; **157**: 1413-1418.
10. Foley RN, Murray AM, Li S, Herzog CA, *et al.* Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. *J Am Soc Nephrol* 2005; **16**: 489-495.
11. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. *N Engl J Med* 1984; **310**: 356-360.
12. Kimmelstiel P, Wilson C. Intercapillary Lesions in the Glomeruli of the Kidney. *Am J Pathol* 1936; **12**: 83-98 87.
13. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. *Kidney Int* 2008; **74**: 22-36.
14. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, *et al.* Podocyte loss and progressive glomerular injury in type II diabetes. *J Clin Invest* 1997; **99**: 342-348.

15. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? *Curr Opin Nephrol Hypertens* 2008; **17**: 32-36.
16. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. *Diabetes* 2005; **54**: 1626-1634.
17. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. *Diabetes* 2006; **55**: 225-233.
18. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. *Diabetologia* 1999; **42**: 1341-1344.
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 2005; **54**: 1615-1625.
20. Wells L, Hart GW. O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. *FEBS Lett* 2003; **546**: 154-158.
21. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, *et al.* High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. *J Clin Invest* 1998; **101**: 160-169.
22. Kolm-Litty V, Tippmer S, Haring HU, Schleicher E. Glucosamine induces translocation of protein kinase C isoenzymes in mesangial cells. *Exp Clin Endocrinol Diabetes* 1998; **106**: 377-383.
23. Sayeski PP, Kudlow JE. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription. *J Biol Chem* 1996; **271**: 15237-15243.
24. Bar-On H, Neshher G, Teitelbaum A, Ziv E. Dolichol-mediated enhanced protein N-glycosylation in experimental diabetes--a possible additional deleterious effect of hyperglycemia. *J Diabetes Complications* 1997; **11**: 236-242.
25. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. *J Am Soc Nephrol* 2003; **14**: S254-258.
26. Lee HB, Yu MR, Yang Y, Jiang Z, *et al.* Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. *J Am Soc Nephrol* 2003; **14**: S241-245.
27. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. *Kidney Int Suppl* 2000; **77**: S13-18.
28. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. *FASEB J* 1999; **13**: 2105-2124.

29. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. *Semin Nephrol* 2003; **23**: 532-543.
30. Hill C, Flyvbjerg A, Gronbaek H, Petrik J, *et al.* The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. *Endocrinology* 2000; **141**: 1196-1208.
31. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, *et al.* Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. *Diabetologia* 1983; **25**: 496-501.
32. Parving HH. Diabetic nephropathy: prevention and treatment. *Kidney Int* 2001; **60**: 2041-2055.
33. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. *N Engl J Med* 1989; **320**: 1161-1165.
34. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM, Jr. The familial risk of end-stage renal disease in African Americans. *Am J Kidney Dis* 1993; **21**: 387-393.
35. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, *et al.* Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1990; **33**: 438-443.
36. McGill MJ, Donnelly R, Molyneaux L, Yue DK. Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM. *Diabetes Res Clin Pract* 1996; **33**: 173-179.
37. Cowie CC, Port FK, Wolfe RA, Savage PJ, *et al.* Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. *N Engl J Med* 1989; **321**: 1074-1079.
38. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, *et al.* Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. *Diabetes* 1998; **47**: 821-830.
39. Iyengar SK, Abboud HE, Goddard KA, Saad MF, *et al.* Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). *Diabetes* 2007; **56**: 1577-1585.
40. Vardarli I, Baier LJ, Hanson RL, Akkoyun I, *et al.* Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. *Kidney Int* 2002; **62**: 2176-2183.
41. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, *et al.* A genome scan for diabetic nephropathy in African Americans. *Kidney Int* 2004; **66**: 1517-1526.
42. Freedman BI, Hicks PJ, Sale MM, Pierson ED, *et al.* A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. *Nephrol Dial Transplant* 2007; **22**: 1131-1135.

-
43. Li WD, Dong C, Li D, Garrigan C, *et al.* A quantitative trait locus influencing fasting plasma glucose in chromosome region 18q22-23. *Diabetes* 2004; **53**: 2487-2491.
 44. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, *et al.* Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. *Diabetes* 2005; **54**: 2320-2327.
 45. Hanson HT, Smith EL. Carnosinase; an enzyme of swine kidney. *J Biol Chem* 1949; **179**: 789-801.
 46. Bando K, Shimotsuji T, Toyoshima H, Hayashi C, *et al.* Fluorometric assay of human serum carnosinase activity in normal children, adults and patients with myopathy. *Ann Clin Biochem* 1984; **21 (Pt 6)**: 510-514.
 47. Kunze N, Kleinkauf H, Bauer K. Characterization of two carnosine-degrading enzymes from rat brain. Partial purification and characterization of a carnosinase and a beta-alanyl-arginine hydrolase. *Eur J Biochem* 1986; **160**: 605-613.
 48. Margolis FL, Grillo M, Grannot-Reisfeld N, Farbman AI. Purification, characterization and immunocytochemical localization of mouse kidney carnosinase. *Biochim Biophys Acta* 1983; **744**: 237-248.
 49. Wolos A, Piekarska K, Glogowski J, Konieczka I. Two molecular forms of swine kidney carnosinase. *Int J Biochem* 1978; **9**: 57-62.
 50. Wood T. Carnosine and carnosinase in rat tissue. *Nature* 1957; **180**: 39-40.
 51. Lenney JF, Peppers SC, Kucera-Orallo CM, George RP. Characterization of human tissue carnosinase. *Biochem J* 1985; **228**: 653-660.
 52. Lenney JF. Human cytosolic carnosinase: evidence of identity with prolinase, a non-specific dipeptidase. *Biol Chem Hoppe Seyler* 1990; **371**: 167-171.
 53. Perry TL, Hansen S, Love DL. Serum-carnosinase deficiency in carnosinaemia. *Lancet* 1968; **1**: 1229-1230.
 54. Lenney JF, George RP, Weiss AM, Kucera CM, *et al.* Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. *Clin Chim Acta* 1982; **123**: 221-231.
 55. Teufel M, Saudek V, Ledig JP, Bernhardt A, *et al.* Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. *J Biol Chem* 2003; **278**: 6521-6531.
 56. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. *Clin Chim Acta* 1991; **196**: 193-205.
 57. McLoughlin DM, Wassif WS, Morton J, Spargo E, *et al.* Metabolic abnormalities associated with skeletal myopathy in severe anorexia nervosa. *Nutrition* 2000; **16**: 192-196.
-

58. Wassif WS, Preedy VR, Summers B, Duane P, *et al.* The relationship between muscle fibre atrophy factor, plasma carnosinase activities and muscle RNA and protein composition in chronic alcoholic myopathy. *Alcohol Alcohol* 1993; **28**: 325-331.
59. Wassif WS, Sherwood RA, Amir A, Idowu B, *et al.* Serum carnosinase activities in central nervous system disorders. *Clin Chim Acta* 1994; **225**: 57-64.
60. Gulewitsch W. Ueber das Carnosin, eine neue organische Base des Fleischextractes.. *Berichte der deutschen chemischen Gesellschaft*, 1900; **33(2)** 1902-1903
61. Boldyrev AA, Severin SE. The histidine-containing dipeptides, carnosine and anserine: distribution, properties and biological significance. *Adv Enzyme Regul* 1990; **30**: 175-194.
62. Bonfanti L, Peretto P, De Marchis S, Fasolo A. Carnosine-related dipeptides in the mammalian brain. *Prog Neurobiol* 1999; **59**: 333-353.
63. Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: its properties, functions and potential therapeutic applications. *Mol Aspects Med* 1992; **13**: 379-444.
64. Horinishi H, Grillo M, Margolis FL. Purification and characterization of carnosine synthetase from mouse olfactory bulbs. *J Neurochem* 1978; **31**: 909-919.
65. Carnegie PR, Ilic MZ, Etheridge MO, Collins MG. Improved high-performance liquid chromatographic method for analysis of histidine dipeptides anserine, carnosine and balenine present in fresh meat. *J Chromatogr* 1983; **261**: 153-157.
66. Bauchart C, Savary-Auzeloux I, Patureau Mirand P, Thomas E, *et al.* Carnosine concentration of ingested meat affects carnosine net release into the portal vein of minipigs. *J Nutr* 2007; **137**: 589-593.
67. Ferraris RP, Diamond J, Kwan WW. Dietary regulation of intestinal transport of the dipeptide carnosine. *Am J Physiol* 1988; **255**: G143-150.
68. Park YJ, Volpe SL, Decker EA. Quantitation of carnosine in humans plasma after dietary consumption of beef. *J Agric Food Chem* 2005; **53**: 4736-4739.
69. Tamaki N, Ikeda T, Fujimoto S, Mizutani N. Carnosine as a histidine source: transport and hydrolysis of exogeneous carnosine by rat intestine. *J Nutr Sci Vitaminol (Tokyo)* 1985; **31**: 607-618.
70. Gardner ML, Illingworth KM, Kelleher J, Wood D. Intestinal absorption of the intact peptide carnosine in man, and comparison with intestinal permeability to lactulose. *J Physiol* 1991; **439**: 411-422.
71. Tamaki N, Funatsuka A, Fujimoto S, Hama T. The utilization of carnosine in rats fed on a histidine-free diet and its effect on the levels of tissue histidine and carnosine. *J Nutr Sci Vitaminol (Tokyo)* 1984; **30**: 541-551.

-
72. Severin SE, Kirzon MV, Kaftanova TM. [Effect of carnosine and anserine on action of isolated frog muscles.]. *Dokl Akad Nauk SSSR* 1953; **91**: 691-694.
 73. Davey CL. The effects of carnosine and anserine on glycolytic reactions in skeletal muscle. *Arch Biochem Biophys* 1960; **89**: 296-302.
 74. Ikeda T, Kimura K, Hama T, Tamaki N. Activation of rabbit muscle fructose 1,6-bisphosphatase by histidine and carnosine. *J Biochem* 1980; **87**: 179-185.
 75. Johnson P, Aldstadt J. Effects of carnosine and anserine on muscle and non-muscle phosphorylases. *Comp Biochem Physiol B* 1984; **78**: 331-333.
 76. Parker CJ, Jr., Ring E. A comparative study of the effect of carnosine on myofibrillar-ATPase activity of vertebrate and invertebrate muscles. *Comp Biochem Physiol* 1970; **37**: 413-419.
 77. Begum G, Cunliffe A, Leveritt M. Physiological role of carnosine in contracting muscle. *Int J Sport Nutr Exerc Metab* 2005; **15**: 493-514.
 78. Nagradova NK. [Studies on the properties of 3-phosphoglyceraldehyde dehydrogenase and of soluble alpha-glycerophosphate dehydrogenase.]. *Biokhimiia* 1959; **24**: 336-344.
 79. Boldyrev AA, Gallant SC, Sukhich GT. Carnosine, the protective, anti-aging peptide. *Biosci Rep* 1999; **19**: 581-587.
 80. Hipkiss AR. Carnosine, a protective, anti-ageing peptide? *Int J Biochem Cell Biol* 1998; **30**: 863-868.
 81. Hipkiss AR. On the enigma of carnosine's anti-ageing actions. *Exp Gerontol* 2009; **44**: 237-242.
 82. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. *Exp Cell Res* 1994; **212**: 167-175.
 83. McFarland GA, Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. *Exp Gerontol* 1999; **34**: 35-45.
 84. Yuneva MO, Bulygina E.R., Gallant S.C., *et al.* . Effect of carnosine on age-induced changes in senescence-accelerated mice. *J Anti Aging Med* 1999; **2**: 337-342
 85. Stvolinsky S, Antipin M, Meguro K, Sato T, *et al.* Effect of Carnosine and Its Trolox-Modified Derivatives on Life Span of *Drosophila melanogaster*. *Rejuvenation Res.*
 86. Yuneva AO, Kramarenko GG, Vetreshchak TV, Gallant S, *et al.* Effect of carnosine on *Drosophila melanogaster* lifespan. *Bull Exp Biol Med* 2002; **133**: 559-561.
 87. Johnson P, Hammer JL. Histidine dipeptide levels in ageing and hypertensive rat skeletal and cardiac muscles. *Comp Biochem Physiol B* 1992; **103**: 981-984.
-

88. Stuerenburg HJ, Kunze K. Concentrations of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles. *Arch Gerontol Geriatr* 1999; **29**: 107-113.
89. Tallon MJ, Harris RC, Maffulli N, Tarnopolsky MA. Carnosine, taurine and enzyme activities of human skeletal muscle fibres from elderly subjects with osteoarthritis and young moderately active subjects. *Biogerontology* 2007; **8**: 129-137.
90. Hipkiss AR. Would carnosine or a carnivorous diet help suppress aging and associated pathologies? *Ann N Y Acad Sci* 2006; **1067**: 369-374.
91. Lee YT, Hsu CC, Lin MH, Liu KS, *et al.* Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *Eur J Pharmacol* 2005; **513**: 145-150.
92. Calabrese V, Colombrita C, Guagliano E, Sapienza M, *et al.* Protective effect of carnosine during nitrosative stress in astroglial cell cultures. *Neurochem Res* 2005; **30**: 797-807.
93. Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. *Proc Natl Acad Sci U S A* 1988; **85**: 3175-3179.
94. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. *FEBS Lett* 1995; **371**: 81-85.
95. Seidler NW. Carnosine prevents the glycation-induced changes in electrophoretic mobility of aspartate aminotransferase. *J Biochem Mol Toxicol* 2000; **14**: 215-220.
96. Yan H, Harding JJ. Carnosine protects against the inactivation of esterase induced by glycation and a steroid. *Biochim Biophys Acta* 2005; **1741**: 120-126.
97. Baran EJ. Metal complexes of carnosine. *Biochemistry (Mosc)* 2000; **65**: 789-797.
98. Dobrota D, Fedorova T, Stvolinsky S, Babusikova E, *et al.* Carnosine protects the brain of rats and Mongolian gerbils against ischemic injury: after-stroke-effect. *Neurochem Res* 2005; **30**: 1283-1288.
99. Fouad AA, El-Rehany MA, Maghraby HK. The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. *Eur J Pharmacol* 2007; **572**: 61-68.
100. Fujii T, Takaoka M, Muraoka T, Kurata H, *et al.* Preventive effect of L-carnosine on ischemia/reperfusion-induced acute renal failure in rats. *Eur J Pharmacol* 2003; **474**: 261-267.
101. Fujii T, Takaoka M, Tsuruoka N, Kiso Y, *et al.* Dietary supplementation of L-carnosine prevents ischemia/reperfusion-induced renal injury in rats. *Biol Pharm Bull* 2005; **28**: 361-363.
102. Gallant S, Kukley M, Stvolinsky S, Bulygina E, *et al.* Effect of carnosine on rats under experimental brain ischemia. *Tohoku J Exp Med* 2000; **191**: 85-99.

-
103. Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. *Free Radic Biol Med* 2000; **28**: 1564-1570.
 104. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. *Biochem Biophys Res Commun* 1998; **248**: 28-32.
 105. Battah S, Ahmed N, Thornalley PJ. Novel anti-glycation therapeutic agents: glyoxalase-1-mimetics. *Int Congr Ser* 2002; **1245**.
 106. Aldini G, Carini M, Beretta G, Bradamante S, *et al.* Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction? *Biochem Biophys Res Commun* 2002; **298**: 699-706.
 107. Aldini G, Facino RM, Beretta G, Carini M. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. *Biofactors* 2005; **24**: 77-87.
 108. Carini M, Aldini G, Beretta G, Arlandini E, *et al.* Acrolein-sequestering ability of endogenous dipeptides: characterization of carnosine and homocarnosine/acrolein adducts by electrospray ionization tandem mass spectrometry. *J Mass Spectrom* 2003; **38**: 996-1006.
 109. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, *et al.* Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. *Neurosci Lett* 1997; **238**: 135-138.
 110. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, *et al.* Pluripotent protective effects of carnosine, a naturally occurring dipeptide. *Ann N Y Acad Sci* 1998; **854**: 37-53.
 111. Hipkiss AR, Brownson C, Carrier MJ. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. *Mech Ageing Dev* 2001; **122**: 1431-1445.
 112. Rashid I, van Reyk DM, Davies MJ. Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. *FEBS Lett* 2007; **581**: 1067-1070.
 113. Sauerhofer S, Yuan G, Braun GS, Deinzer M, *et al.* L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. *Diabetes* 2007; **56**: 2425-2432.
 114. Hou WC, Chen HJ, Lin YH. Antioxidant peptides with Angiotensin converting enzyme inhibitory activities and applications for Angiotensin converting enzyme purification. *J Agric Food Chem* 2003; **51**: 1706-1709.
 115. Nakagawa K, Ueno A, Nishikawa Y. Interactions between carnosine and captopril on free radical scavenging activity and angiotensin-converting enzyme activity in vitro. *Yakugaku Zasshi* 2006; **126**: 37-42.
-

116. Taal MW, Brenner BM. Achieving maximal renal protection in nondiabetic chronic renal disease. *Am J Kidney Dis* 2001; **38**: 1365-1371.
117. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, *et al.* Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; **345**: 861-869.
118. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. *Nephrol Dial Transplant* 1989; **4**: 859-863.
119. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837-853.
120. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. *Lancet* 1983; **1**: 1175-1179.
121. Freedman BI, Bowden DW, Sale MM, Langefeld CD, *et al.* Genetic susceptibility contributes to renal and cardiovascular complications of type 2 diabetes mellitus. *Hypertension* 2006; **48**: 8-13.
122. Boldyrev A, Bulygina E, Leinsoo T, Petrushanko I, *et al.* Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. *Comp Biochem Physiol B Biochem Mol Biol* 2004; **137**: 81-88.
123. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, *et al.* [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. *Ugeskr Laeger* 2001; **163**: 5519-5524.
124. Martoglio B, Dobberstein B. Signal sequences: more than just greasy peptides. *Trends Cell Biol* 1998; **8**: 410-415.
125. von Heijne G. Signal sequences. The limits of variation. *J Mol Biol* 1985; **184**: 99-105.
126. Zschocke J, Nebel A, Wicks K, Peters V, *et al.* Allelic variation in the CNDP1 gene and its lack of association with longevity and coronary heart disease. *Mech Ageing Dev* 2006; **127**: 817-820.
127. Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. *Trends Cell Biol* 2005; **15**: 364-370.
128. Fleisher LD, Rassin DK, Wisniewski K, Salwen HR. Carnosinase deficiency: a new variant with high residual activity. *Pediatr Res* 1980; **14**: 269-271.
129. Gjessing LR, Lunde HA, Morkrid L, Lenney JF, *et al.* Inborn errors of carnosine and homocarnosine metabolism. *J Neural Transm Suppl* 1990; **29**: 91-106.

-
130. Duane P, Peters TJ. Serum carnosinase activities in patients with alcoholic chronic skeletal muscle myopathy. *Clin Sci (Lond)* 1988; **75**: 185-190.
 131. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. *Am J Kidney Dis* 1999; **34**: 795-808.
 132. Parving HH. Hypertension Optimal Treatment (HOT) trial. *Lancet* 1998; **352**: 574-575.
 133. Riedl E, Koeppl H, Brinkkoetter P, Sternik P, *et al.* A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. *Diabetes* 2007; **56**: 2410-2413.
 134. Hipkiss A, Preston J, Himsworth D, Worthington V, *et al.* Pluripotent protective effects of carnosine, a naturally occurring dipeptide. *Ann N Y Acad Sci* 1998; **854**: 37-53.
 135. Fouad A, El-Rehany M, Maghraby H. The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. *Eur J Pharmacol* 2007; **572**: 61-68.
 136. Kurata H, Fujii T, Tsutsui H, Katayama T, *et al.* Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. *J Pharmacol Exp Ther* 2006; **319**: 640-647.
 137. Rajanikant G, Zemke D, Senut M, Frenkel M, *et al.* Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. *Stroke* 2007; **38**: 3023-3031.
 138. Wanic K, Placha G, Dunn J, Smiles A, *et al.* Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. *Diabetes* 2008; **57**: 2547-2551.
 139. Bakker SJ, Alkhalaf A, Tarnow L, Navis G. Re: Exclusion of polymorphisms in carnosinase genes (CNDP1 and CNDP2) as a cause of diabetic nephropathy in type 1 diabetes: results of large case-control and follow-up studies. *Diabetes* 2008; **57**: e16; author reply e17.
 140. Molinari M. N-glycan structure dictates extension of protein folding or onset of disposal. *Nat Chem Biol* 2007; **3**: 313-320.
 141. Broschat KO, Gorka C, Page JD, Martin-Berger CL, *et al.* Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate. *J Biol Chem* 2002; **277**: 14764-14770.
 142. Lau KS, Partridge EA, Grigorian A, Silvescu CI, *et al.* Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. *Cell* 2007; **129**: 123-134.
 143. Sasai K, Ikeda Y, Fujii T, Tsuda T, *et al.* UDP-GlcNAc concentration is an important factor in the biosynthesis of beta1,6-branched oligosaccharides: regulation based on
-

- the kinetic properties of N-acetylglucosaminyltransferase V. *Glycobiology* 2002; **12**: 119-127.
144. Teufel M, Saudek V, Ledig J, Bernhardt A, *et al.* Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. *The Journal of biological chemistry* 2003; **278**: 6521-6531.
145. Antenos M, Stemler M, Boime I, Woodruff TK. N-linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaA-subunit dimers. *Mol Endocrinol* 2007; **21**: 1670-1684.
146. Li Y, Yang X, Nguyen AH, Brockhausen I. Requirement of N-glycosylation for the secretion of recombinant extracellular domain of human Fas in HeLa cells. *Int J Biochem Cell Biol* 2007; **39**: 1625-1636.
147. Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. *Blood* 2009; **113**: 929-935.
148. Olivari S, Molinari M. Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. *FEBS letters* 2007; **581**: 3658-3664.
149. Ellgaard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. *Science (New York, NY)* 1999; **286**: 1882-1888.
150. Ito K, Seri A, Kimura F, Matsudomi N. Site-specific glycosylation at Asn-292 in ovalbumin is essential to efficient secretion in yeast. *Journal of biochemistry* 2007; **141**: 193-199.
151. Pradere JP, Tarnus E, Gres S, Valet P, *et al.* Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase. *Biochimica et biophysica acta* 2007; **1771**: 93-102.
152. Gladysheva IP, King SM, Houng AK. N-glycosylation modulates the cell-surface expression and catalytic activity of corin. *Biochemical and biophysical research communications* 2008; **373**: 130-135.
153. Pacheco B, Maccarana M, Goodlett DR, Malmstrom A, *et al.* Identification of the active site of DS-epimerase 1 and requirement of N-glycosylation for enzyme function. *The Journal of biological chemistry* 2009; **284**: 1741-1747.
154. Wendt T, Tanji N, Guo J, Hudson B, *et al.* Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. *J Am Soc Nephrol* 2003; **14**: 1383-1395.
155. Bierhaus A, Hofmann M, Ziegler R, Nawroth P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. *Cardiovasc Res* 1998; **37**: 586-600.
156. Berry E, Ziv E, Bar-On H. Protein and glycoprotein synthesis and secretion by the diabetic liver. *Diabetologia* 1980; **19**: 535-540.

-
157. Berry E, Ziv E, Bar-On H. Lipoprotein secretion by isolated perfused livers from streptozotocin-diabetic rats. *Diabetologia* 1981; **21**: 402-408.
 158. Jones J, Krag SS, Betenbaugh MJ. Controlling N-linked glycan site occupancy. *Biochimica et biophysica acta* 2005; **1726**: 121-137.
 159. Peters V, Kebbewar M, Jansen EW, Jakobs C, *et al.* Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. *Amino acids* 2009.
 160. Harris RC, Tallon MJ, Dunnett M, Boobis L, *et al.* The absorption of orally supplied beta-alanine and its effect on muscle carnosine synthesis in human vastus lateralis. *Amino Acids* 2006; **30**: 279-289.
 161. Hill CA, Harris RC, Kim HJ, Harris BD, *et al.* Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. *Amino Acids* 2007; **32**: 225-233.
 162. Derave W, Ozdemir MS, Harris RC, Pottier A, *et al.* beta-Alanine supplementation augments muscle carnosine content and attenuates fatigue during repeated isokinetic contraction bouts in trained sprinters. *J Appl Physiol* 2007; **103**: 1736-1743.
 163. Stout JR, Cramer JT, Zoeller RF, Torok D, *et al.* Effects of beta-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women. *Amino Acids* 2007; **32**: 381-386.
 164. Tabakman R, Lazarovici P, Kohen R. Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. *J Neurosci Res* 2002; **68**: 463-469.
 165. De Marchis S, Modena C, Peretto P, Giffard C, *et al.* Carnosine-like immunoreactivity in the central nervous system of rats during postnatal development. *J Comp Neurol* 2000; **426**: 378-390.
 166. Baguet A, Reyngoudt H, Pottier A, Everaert I, *et al.* Carnosine loading and washout in human skeletal muscles. *J Appl Physiol* 2009; **106**: 837-842.
 167. Drozak J, Veiga-da-Cunha M, Vertommen D, Stroobant V, *et al.* Molecular identification of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1). *J Biol Chem* **285**: 9346-9356.
 168. Riedl E, Koeppl H, Brinkkoetter P, Sternik P, *et al.* A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. *Diabetes* 2007; **56**: 2410-2413.
 169. Peters V, Kebbewar M, Jansen EW, Jakobs C, *et al.* Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity. *Amino Acids* **38**: 1607-1615.
-

170. Riedl E, Koepfel H, Pfister F, Peters V, *et al.* N-glycosylation of carnosinase influences protein secretion and enzyme activity: implications for hyperglycemia. *Diabetes* **59**: 1984-1990.
171. Riedl E, Koepfel H, Pfister F, Peters V, *et al.* N-Glycosylation of Carnosinase influences protein secretion and enzyme activity: Implications for hyperglycemia. *Diabetes*.
172. Murphey WH, Patchen L, Lindmark DG. Carnosinase: A fluorometric assay and demonstration of two electrophoretic forms in human tissue extracts. *Clinica Chimica Acta* 1972; **42**: 309-314.
173. Vistoli G, Pedretti A, Cattaneo M, Aldini G, *et al.* Homology modeling of human serum carnosinase, a potential medicinal target, and MD simulations of its allosteric activation by citrate. *J Med Chem* 2006; **49**: 3269-3277.
174. Crush KG. Carnosine and related substances in animal tissues. *Comp Biochem Physiol* 1970; **34**: 3-30.
175. Bauer K. Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain. *Neurochem Res* 2005; **30**: 1339-1345.
176. Aydogan S, Yapislar H, Artis S, Aydogan B. Impaired erythrocytes deformability in H₂O₂-induced oxidative stress: protective effect of L-carnosine. *Clin Hemorheol Microcirc* 2008; **39**: 93-98.
177. Baslow MH. A novel key-lock mechanism for inactivating amino acid neurotransmitters during transit across extracellular space. *Amino Acids* **38**: 51-55.
178. Min J, Senut MC, Rajanikant K, Greenberg E, *et al.* Differential neuroprotective effects of carnosine, anserine, and N-acetyl carnosine against permanent focal ischemia. *J Neurosci Res* 2008; **86**: 2984-2991.
179. Kendrick IP, Harris RC, Kim HJ, Kim CK, *et al.* The effects of 10 weeks of resistance training combined with beta-alanine supplementation on whole body strength, force production, muscular endurance and body composition. *Amino Acids* 2008; **34**: 547-554.
180. Kim HJ. Comparison of the carnosine and taurine contents of vastus lateralis of elderly Korean males, with impaired glucose tolerance, and young elite Korean swimmers. *Amino Acids* 2009; **36**: 359-363.
181. Perry TL, Hansen S, Stedman D, Love D. Homocarnosine in human cerebrospinal fluid: an age-dependent phenomenon. *J Neurochem* 1968; **15**: 1203-1206.
182. Bando K, Ichihara K, Toyoshima H, Shimotuji T, *et al.* Decreased activity of carnosinase in serum of patients with chronic liver disorders. *Clin Chem* 1986; **32**: 1563-1565.
183. Roesel RA. Carnosinuria and serum carnosinase deficiency in a child with congenital myopathy. *Federation proceedings* 1981; **40**: 461-465.

-
184. Balion CM, Benson C, Raina PS, Papaioannou A, *et al.* Brain type carnosinase in dementia: a pilot study. *BMC Neurol* 2007; **7**: 38.
 185. Jansen EE, Gibson KM, Shigematsu Y, Jakobs C, *et al.* A novel, quantitative assay for homocarnosine in cerebrospinal fluid using stable-isotope dilution liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2006; **830**: 196-200.
 186. Schonherr J. Analysis of products of animal origin in feeds by determination of carnosine and related dipeptides by high-performance liquid chromatography. *J Agric Food Chem* 2002; **50**: 1945-1950.
 187. Margolis FL, Grillo M, Brown CE, Williams TH, *et al.* Enzymatic and immunological evidence for two forms of carnosinase in the mouse. *Biochim Biophys Acta* 1979; **570**: 311-323.
 188. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, *et al.* The changing natural history of nephropathy in type I diabetes. *Am J Med* 1985; **78**: 785-794.
 189. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. *Kidney Int* 1989; **35**: 681-687.
 190. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, *et al.* Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. *Diabetes Care* 1995; **18**: 182-187.
 191. Schmitz A, Vaeth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. *Diabetologia* 1994; **37**: 1251-1258.
 192. Ravid M, Brosh D, Ravid-Safran D, Levy Z, *et al.* Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. *Arch Intern Med* 1998; **158**: 998-1004.
 193. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. *BMJ* 1997; **314**: 783-788.
 194. Mooyaart AL, Zutinic A, Bakker SJ, Grootendorst DC, *et al.* Association between CNDP1 genotype and diabetic nephropathy is sex specific. *Diabetes* **59**: 1555-1559.
 195. Peters V, Jansen EE, Jakobs C, Riedl E, *et al.* Anserine inhibits carnosine degradation but in human serum carnosinase (CN1) is not correlated with histidine dipeptide concentration. *Clin Chim Acta*.
 196. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. *J Am Soc Nephrol* 2005; **16 Suppl 1**: S30-33.
 197. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by
-

- autocrine activation of transforming growth factor-beta. *J Clin Invest* 1994; **93**: 536-542.
198. McGowan TA, Dunn SR, Falkner B, Sharma K. Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans. *Clin J Am Soc Nephrol* 2006; **1**: 263-268.
199. Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: role of novel signaling pathways. *Cytokine Growth Factor Rev* 2000; **11**: 115-123.
200. Sraer JD, Delarue F, Hagege J, Feunteun J, *et al.* Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. *Kidney international* 1996; **49**: 267-270.
201. Tesseur I, Zou K, Berber E, Zhang H, *et al.* Highly sensitive and specific bioassay for measuring bioactive TGF-beta. *BMC cell biology* 2006; **7**: 15.
202. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. *Faseb J* 2004; **18**: 816-827.
203. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. *J Am Soc Nephrol* 2004; **15 Suppl 1**: S55-57.
204. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. *J Cell Sci* 2005; **118**: 3573-3584.
205. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003; **425**: 577-584.
206. Tsuchida K, Zhu Y, Siva S, Dunn SR, *et al.* Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. *Kidney Int* 2003; **63**: 2000-2009.
207. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, *et al.* Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. *Am J Pathol* 2008; **173**: 1085-1099.
208. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. *J Biol Chem* 2000; **275**: 20315-20323.
209. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, *et al.* Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *The EMBO journal* 2002; **21**: 1743-1753.
210. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. *Nat Rev Nephrol* 2009; **5**: 203-211.
211. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. *Nephrology (Carlton, Vic)* 2005; **10 Suppl**: S11-13.

-
212. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiology. *Am J Physiol Renal Physiol* 2007; **292**: F905-911.
 213. Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. *Endocrine* 2009; **35**: 1-10.
 214. Zhang SX, Wang JJ, Lu K, Mott R, *et al.* Therapeutic potential of angiostatin in diabetic nephropathy. *J Am Soc Nephrol* 2006; **17**: 475-486.
 215. Inada A, Nagai K, Arai H, Miyazaki J, *et al.* Establishment of a diabetic mouse model with progressive diabetic nephropathy. *Am J Pathol* 2005; **167**: 327-336.
 216. Singh R, Song RH, Alavi N, Pegoraro AA, *et al.* High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. *Experimental nephrology* 2001; **9**: 249-257.
 217. Romanic AM, Burns-Kurtis CL, Ao Z, Arleth AJ, *et al.* Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. *Am J Physiol Renal Physiol* 2001; **281**: F309-317.
 218. Kang BP, Frencher S, Reddy V, Kessler A, *et al.* High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. *Am J Physiol Renal Physiol* 2003; **284**: F455-466.
 219. Yamagishi S, Inagaki Y, Okamoto T, Amano S, *et al.* Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. *J Biol Chem* 2002; **277**: 20309-20315.
 220. Baba K, Minatoguchi S, Sano H, Kagawa T, *et al.* Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings. *Nephrology (Carlton)* 2004; **9**: 94-99.
 221. Kumar D, Robertson S, Burns KD. Evidence of apoptosis in human diabetic kidney. *Mol Cell Biochem* 2004; **259**: 67-70.
 222. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, *et al.* Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. *Nat Med* 2007; **13**: 1349-1358.
 223. Mooyaart AL, van Valkengoed IG, Shaw PK, Peters V, *et al.* Lower frequency of the 5/5 homozygous CNDP1 genotype in South Asian Surinamese. *Diabetes Res Clin Pract* 2009; **85**: 272-278.
 224. Fuji Y, Matura T, Kai M, Kawasaki H, *et al.* Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells. *Jpn J Pharmacol* 2000; **84**: 63-70.
 225. Matsuu-Matsuyama M, Shichijo K, Okaichi K, Nakayama T, *et al.* Protection by polaprezinc against radiation-induced apoptosis in rat jejunal crypt cells. *J Radiat Res (Tokyo)* 2008; **49**: 341-347.
-

226. Omatsu T, Naito Y, Handa O, Mizushima K, *et al.* Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. *J Gastroenterol.*
227. Odashima M, Otaka M, Jin M, Konishi N, *et al.* Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc L-carnosine. *Dig Dis Sci* 2002; **47**: 2799-2804.
228. Baykara B, Tekmen I, Pekcetin C, Ulukus C, *et al.* The protective effects of carnosine and melatonin in ischemia-reperfusion injury in the rat liver. *Acta Histochem* 2009; **111**: 42-51.
229. Kurata H, Fujii T, Tsutsui H, Katayama T, *et al.* Renoprotective effects of l-carnosine on ischemia/reperfusion-induced renal injury in rats. *J Pharmacol Exp Ther* 2006; **319**: 640-647.
230. Hammes HP, Alt A, Niwa T, Clausen JT, *et al.* Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. *Diabetologia* 1999; **42**: 728-736.
231. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, *et al.* Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. *J Clin Invest* 1998; **101**: 1142-1147.
232. Aruoma OI, Loughton MJ, Halliwell B. Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo? *Biochem J* 1989; **264**: 863-869.
233. Decker EA, Livisay SA, Zhou S. A re-evaluation of the antioxidant activity of purified carnosine. *Biochemistry (Mosc)* 2000; **65**: 766-770.
234. Davey CL. The significance of carnosine and anserine in striated skeletal muscle. *Arch Biochem Biophys* 1960; **89**: 303-308.
235. Dunnett M, Harris RC. Influence of oral beta-alanine and L-histidine supplementation on the carnosine content of the gluteus medius. *Equine Vet J Suppl* 1999; **30**: 499-504.
236. Yoshimura A, Uda S, Inui K, Nemoto T, *et al.* Expression of bcl-2 and bax in glomerular disease. *Nephrol Dial Transplant* 1999; **14 Suppl 1**: 55-57.
237. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? *Kidney Int* 1998; **54**: 687-697.
238. Mundel P, Shankland SJ. Podocyte biology and response to injury. *J Am Soc Nephrol* 2002; **13**: 3005-3015.
239. Nakamura T, Ushiyama C, Suzuki S, Hara M, *et al.* The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. *Am J Nephrol* 2000; **20**: 175-179.

-
240. Steffes MW, Schmidt D, McCrery R, Basgen JM. Glomerular cell number in normal subjects and in type 1 diabetic patients. *Kidney Int* 2001; **59**: 2104-2113.
241. Wanic K, Placha G, Dunn J, Smiles A, *et al.* Exclusion of polymorphisms in carnosinase genes (CNDP1 & CNDP2) as cause of diabetic nephropathy in type 1 diabetes mellitus. Results of large case - control and follow - up studies. *Diabetes* 2008.
242. Alkhalaf A, Bakker SJ, Bilo HJ, Gans RO, *et al.* A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. *Diabetologia*.
243. Blobel G, Walter P, Chang CN, Goldman BM, *et al.* Translocation of proteins across membranes: the signal hypothesis and beyond. *Symp Soc Exp Biol* 1979; **33**: 9-36.
244. Visvikis S, Chan L, Siest G, Drouin P, *et al.* An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. *Hum Genet* 1990; **84**: 373-375.
245. Nilsson LN, Das S, Potter H. Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. *Neurochem Int* 2001; **39**: 361-370.
246. Jaakkola U, Kakko T, Seppala H, Vainio-Jylha E, *et al.* The Leu7Pro polymorphism of the signal peptide of neuropeptide Y (NPY) gene is associated with increased levels of inflammatory markers preceding vascular complications in patients with type 2 diabetes. *Microvasc Res*.
247. Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. *Proc Natl Acad Sci U S A* 1996; **93**: 4471-4473.
248. Hounsell EF, Young M, Davies MJ. Glycoprotein changes in tumours: a renaissance in clinical applications. *Clin Sci* 1997; **93**: 287-293.
249. Axford J. The impact of glycobiology on medicine. *Trends Immunol* 2001; **22**: 237-239.
250. Yao D, Taguchi T, Matsumura T, Pestell R, *et al.* High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. *J Biol Chem* 2007; **282**: 31038-31045.
251. Carlsson J, Gullstrand C, Ludvigsson J, Lundstrom I, *et al.* Detection of global glycosylation changes of serum proteins in type 1 diabetes using a lectin panel and multivariate data analysis. *Talanta* 2008; **76**: 333-337.
252. Schoen P, Everts H, de Boer T, van Oeveren W. Serum Carnosinase Activity in Plasma and Serum: Validation of a Method and Values in Cardiopulmonary Bypass Surgery. *Clin Chem* 2003; **49**: 1930-1932.
253. Tabakman R, Jiang H, Levine RA, Kohen R, *et al.* Apoptotic characteristics of cell death and the neuroprotective effect of homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. *J Neurosci Res* 2004; **75**: 499-507.
-

254. Jackson MC, Scollard DM, Mack RJ, Lenney JF. Localization of a novel pathway for the liberation of GABA in the human CNS. *Brain Res Bull* 1994; **33**: 379-385.
255. Backonja M, Beydoun A, Edwards KR, Schwartz SL, *et al.* Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial. *JAMA* 1998; **280**: 1831-1836.
256. Fitzpatrick DW, Fisher H. Carnosine, histidine, and wound healing. *Surgery* 1982; **91**: 56-60.
257. Nagai K, Suda T, Kawasaki K, Mathuura S. Action of carnosine and beta-alanine on wound healing. *Surgery* 1986; **100**: 815-821.
258. Bergstrom JS, SE) Method and compositions for the treatment of renal failure. In (vol 6017942), United States, Baxter International Inc. (Deerfield, IL), 2000
259. Inagaki TS, JP), Tagashira, Eijiro (Saitama, JP), Takaya, Masahiro (Shiga, JP), Nishimura, Yasuhiro (Osaka, JP) Preventive and therapeutic agent against liver disorder. In (vol 4927817), United States, Zeria Pharmaceutical Co., Ltd. (Tokyo, JP), Hamari Chemicals, Ltd. (Osaka, JP), 1990
260. Yamaguchi MS, JP): Osteogenesis promoter. In (vol 5294634), United States, Zeria Pharmaceutical Co., Ltd. (Tokyo, JP), Hamari Chemicals Co., Ltd. (Osaka, JP), 1994
261. Grigg GWLC, AU): Compositions And Methods For The Treatment Of Skin Damage. In (vol 20070275084), United States, 2007
262. Del Soldato PMM, IT): Drugs for diabetes. In (vol 20040023890), United States, 2004
263. Zschocke J, Nebel A, Wicks K, Peters V, *et al.* Allelic variation in the CNDP1 gene and its lack of association with longevity and coronary heart disease. *Mechanisms of Ageing and Development* 2006; **127**: 817-820.
264. Everaert I, Mooyaart A, Baguet A, Zutinic A, *et al.* Vegetarianism, female gender and increasing age, but not <i>CNDP1</i> genotype, are associated with reduced muscle carnosine levels in humans. *Amino Acids*: 1-9.

ⁱ www.who.int